These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 15905721)

  • 1. The choice of region of interest measures in contrast-enhanced magnetic resonance image characterization of experimental breast tumors.
    Preda A; Turetschek K; Daldrup H; Floyd E; Novikov V; Shames DM; Roberts TP; Carter WO; Brasch RC
    Invest Radiol; 2005 Jun; 40(6):349-54. PubMed ID: 15905721
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Correlation of dynamic contrast-enhanced MR imaging with histologic tumor grade: comparison of macromolecular and small-molecular contrast media.
    Daldrup H; Shames DM; Wendland M; Okuhata Y; Link TM; Rosenau W; Lu Y; Brasch RC
    AJR Am J Roentgenol; 1998 Oct; 171(4):941-9. PubMed ID: 9762973
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MR imaging characterization of microvessels in experimental breast tumors by using a particulate contrast agent with histopathologic correlation.
    Turetschek K; Huber S; Floyd E; Helbich T; Roberts TP; Shames DM; Tarlo KS; Wendland MF; Brasch RC
    Radiology; 2001 Feb; 218(2):562-9. PubMed ID: 11161179
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessment of a rapid clearance blood pool MR contrast medium (P792) for assays of microvascular characteristics in experimental breast tumors with correlations to histopathology.
    Turetschek K; Floyd E; Shames DM; Roberts TP; Preda A; Novikov V; Corot C; Carter WO; Brasch RC
    Magn Reson Med; 2001 May; 45(5):880-6. PubMed ID: 11323815
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MRI assessment of microvascular characteristics in experimental breast tumors using a new blood pool contrast agent (MS-325) with correlations to histopathology.
    Turetschek K; Floyd E; Helbich T; Roberts TP; Shames DM; Wendland MF; Carter WO; Brasch RC
    J Magn Reson Imaging; 2001 Sep; 14(3):237-42. PubMed ID: 11536400
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MRI tumor characterization using Gd-GlyMe-DOTA-perfluorooctyl-mannose-conjugate (Gadofluorine M), a protein-avid contrast agent.
    Raatschen HJ; Swain R; Shames DM; Fu Y; Boyd Z; Zierhut ML; Wendland MF; Misselwitz B; Weinmann HJ; Wolf KJ; Brasch RC
    Contrast Media Mol Imaging; 2006; 1(3):113-20. PubMed ID: 17193687
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumor microvascular characterization using ultrasmall superparamagnetic iron oxide particles (USPIO) in an experimental breast cancer model.
    Turetschek K; Roberts TP; Floyd E; Preda A; Novikov V; Shames DM; Carter WO; Brasch RC
    J Magn Reson Imaging; 2001 Jun; 13(6):882-8. PubMed ID: 11382948
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of Gadomer-17 and gadopentetate dimeglumine for differentiation of benign from malignant breast tumors with MR imaging.
    Daldrup-Link HE; Shames DM; Wendland M; Mühler A; Gossmann A; Rosenau W; Brasch RC
    Acad Radiol; 2000 Nov; 7(11):934-44. PubMed ID: 11089696
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Correlation of dynamic contrast-enhanced magnetic resonance imaging with histologic tumor grade: comparison of macromolecular and small-molecular contrast media.
    Daldrup H; Shames DM; Wendland M; Okuhata Y; Link TM; Rosenau W; Lu Y; Brasch RC
    Pediatr Radiol; 1998 Feb; 28(2):67-78. PubMed ID: 9472047
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quantitative gadopentetate-enhanced MRI of breast tumors: testing of different analytic methods.
    Helbich TH; Roberts TP; Gossmann A; Wendland MF; Shames DM; Adachi M; Yang S; Huber S; Daldrup H; Brasch RC
    Magn Reson Med; 2000 Dec; 44(6):915-24. PubMed ID: 11108629
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mammary carcinoma model: correlation of macromolecular contrast-enhanced MR imaging characterizations of tumor microvasculature and histologic capillary density.
    van Dijke CF; Brasch RC; Roberts TP; Weidner N; Mathur A; Shames DM; Mann JS; Demsar F; Lang P; Schwickert HC
    Radiology; 1996 Mar; 198(3):813-8. PubMed ID: 8628876
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Magnetic resonance characterization of tumor microvessels in experimental breast tumors using a slow clearance blood pool contrast agent (carboxymethyldextran-A2-Gd-DOTA) with histopathological correlation.
    Preda A; Novikov V; Möglich M; Floyd E; Turetschek K; Shames DM; Roberts TP; Corot C; Carter WO; Brasch RC
    Eur Radiol; 2005 Nov; 15(11):2268-75. PubMed ID: 16012822
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Correlation of microvascular permeability derived from dynamic contrast-enhanced MR imaging with histologic grade and tumor labeling index: a study in human brain tumors.
    Roberts HC; Roberts TP; Bollen AW; Ley S; Brasch RC; Dillon WP
    Acad Radiol; 2001 May; 8(5):384-91. PubMed ID: 11345268
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gadopentetate dimeglumine versus ultrasmall superparamagnetic iron oxide for dynamic contrast-enhanced MR imaging of tumor angiogenesis in human colon carcinoma in mice.
    de Lussanet QG; Backes WH; Griffioen AW; van Engelshoven JM; Beets-Tan RG
    Radiology; 2003 Nov; 229(2):429-38. PubMed ID: 14595147
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quantification of breast tumor microvascular permeability with feruglose-enhanced MR imaging: initial phase II multicenter trial.
    Daldrup-Link HE; Rydland J; Helbich TH; Bjørnerud A; Turetschek K; Kvistad KA; Kaindl E; Link TM; Staudacher K; Shames D; Brasch RC; Haraldseth O; Rummeny EJ
    Radiology; 2003 Dec; 229(3):885-92. PubMed ID: 14576446
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intra-individual comparison of different gadolinium-based contrast agents in the quantitative evaluation of C6 glioma with dynamic contrast-enhanced magnetic resonance imaging.
    Li Y; Liu G; Lou X; Chen Z; Ma L
    Sci China Life Sci; 2017 Jan; 60(1):11-15. PubMed ID: 28078511
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of tamoxifen in an experimental model of breast tumor studied by dynamic contrast-enhanced magnetic resonance imaging and different contrast agents.
    Marzola P; Ramponi S; Nicolato E; Lovati E; Sandri M; Calderan L; Crescimanno C; Merigo F; Sbarbati A; Grotti A; Vultaggio S; Cavagna F; Lorusso V; Osculati F
    Invest Radiol; 2005 Jul; 40(7):421-9. PubMed ID: 15973133
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dynamic contrast-enhanced MRI using macromolecular contrast media for monitoring the response to isolated limb perfusion in experimental soft-tissue sarcomas.
    Preda A; Wielopolski PA; Ten Hagen TL; van Vliet M; Veenland JF; Ambagtsheer G; van Tiel ST; Vogel MW; Eggermont AM; Krestin GP; van Dijke CF
    MAGMA; 2004 Dec; 17(3-6):296-302. PubMed ID: 15480945
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identifying tumor vascular permeability heterogeneity with magnetic resonance imaging contrast agents.
    Aref M; Brechbiel M; Wiener EC
    Invest Radiol; 2002 Apr; 37(4):178-92. PubMed ID: 11923640
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Manganese-enhanced magnetic resonance imaging for early detection and characterization of breast cancers.
    Alhamami M; Bayat Mokhtari R; Ganesh T; Tchouala Nofiele J; Yeger H; Margaret Cheng HL
    Mol Imaging; 2014; 13():. PubMed ID: 25060340
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.